Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)

Patent analysis indicates that most FXII(a) inhibitors remain in early preclinical development, though a growing subset has shown <i>in vivo</i> efficacy in models of thrombosis, HAE, sepsis, and neuroinflammation. The breadth and pace of 2020-2025 filings, together with accumulating translational data, should accelerate progression from patents to clinical candidates, particularly for contact-activation indications (e.g. device-related thrombosis). Resolving full-length FXII/α-FXIIa structures would further enable allosteric inhibitors design.